Firebrick receives $250,000 R&D Tax Incentive
Key points
- Firebrick Pharma receives $250,000 R&D Tax Incentive payment
- Incentive related to $576,000 in reported R&D costs in FY25
- Funds will support further development of Nasodine and new product development
Full summary
Firebrick Pharma Limited (ASX:FRE) has announced that it has received an RDTI (R&D Tax Incentive) payment of $250,000 for eligible R&D expenditure incurred in 2024/25. The incentive payment related to $576,000 in reported R&D costs in the FY25 year, associated with the Company's further development of Nasodine as a broad spectrum antimicrobial agent and other new product development. Dr Peter Molloy, Executive Director of Firebrick Pharma, welcomed the 'valuable injection of non-dilutive funds from the R&D tax incentive', which will support the company's ongoing research and development activities.
Summary generated by a large language model. Please interpret with care.